Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy

• Published in: Pflügers Archiv 2019-05, Vol.471 (5), p.719-733
• Main Authors: Kraft, Theresia, Montag, Judith
• Format: Article
• Language: English
• Subjects: Allelic Imbalance; Animals; Biomedical and Life Sciences; Biomedicine; Cardiac Myosins - genetics; Cardiac Myosins - metabolism; Cardiomyocytes; Cardiomyopathy; Cardiomyopathy, Hypertrophic - genetics; Cardiomyopathy, Hypertrophic - metabolism; Cardiomyopathy, Hypertrophic - physiopathology; Cell Biology; Contractility; Fibrosis; Human Physiology; Humans; Invited Review; Molecular Medicine; Mutation; Myocardial Contraction; Myocardium; Myocytes, Cardiac - metabolism; Myocytes, Cardiac - physiology; Myosin; Neurosciences; Phenotypes; Proteins; Receptors; Transcription; Ventricle
• ISSN: 0031-6768; 1432-2013
• DOI: 10.1007/s00424-019-02260-9

Hypertrophic cardiomyopathy (HCM) is mainly caused by mutations in sarcomeric proteins. Thirty to forty percent of identified mutations are found in the ventricular myosin heavy chain (β-MyHC). A common mechanism explaining how numerous mutations in several different proteins induce a similar HCM-phenotype is unclear. It was proposed that HCM-mutations cause hypercontractility, which for some mutations is thought to result from mutation-induced unlocking of myosin heads from a so-called super-relaxed state (SRX). The SRX was suggested to be related to the “interacting head motif,” i.e., pairs of myosin heads folded back onto their S2-region. Here, we address these structural states of myosin in context of earlier work on weak binding cross-bridges. However, not all HCM-mutations cause hypercontractility and/or are involved in the interacting head motif. But most likely, all mutations alter the force generating mechanism, yet in different ways, possibly including inhibition of SRX. Such functional—hyper- and hypocontractile—changes are the basis of our previously proposed concept stating that contractile imbalance due to unequal fractions of mutated and wildtype protein among individual cardiomyocytes over time will induce cardiomyocyte disarray and fibrosis, hallmarks of HCM. Studying β-MyHC-mutations, we found substantial contractile variability from cardiomyocyte to cardiomyocyte within a patient’s myocardium, much higher than in controls. This was paralleled by a similarly variable fraction of mutant MYH7 -mRNA (cell-to-cell allelic imbalance), due to random, burst-like transcription, independent for mutant and wildtype MYH7 -alleles. Evidence suggests that HCM-mutations in other sarcomeric proteins follow the same disease mechanism.